Meeting of the Advisory Committee on Blood and Tissue Safety and Availability, 64424-64425 [2015-26904]
Download as PDF
<![CDATA[
64424
Federal Register / Vol. 80, No. 205 / Friday, October 23, 2015 / Notices
range of professional disciplines and
educational levels.
DATES: The meeting will take place
November 17, 2015, from 9 a.m. to
approximately 5 p.m.
ADDRESSES: Hilton Arlington Hotel, 950
North Stafford Street, Arlington, VA
22203.
Lisa
M. Lee, Executive Director, Presidential
Commission for the Study of Bioethical
Issues, 1425 New York Avenue NW.,
Suite C–100, Washington, DC 20005.
Telephone: 202–233–3960. Email:
Lisa.Lee@bioethics.gov. Additional
information may be obtained at
www.bioethics.gov.
FOR FURTHER INFORMATION CONTACT:
Pursuant
to the Federal Advisory Committee Act
of 1972, Public Law 92–463, 5 U.S.C.
app. 2, notice is hereby given for the
twenty-third meeting of the
Commission. The meeting will be open
to the public with attendance limited to
space available. The meeting will also
be webcast at www.bioethics.gov.
Under authority of Executive Order
13521, dated November 24, 2009, the
President established the Commission.
The Commission is an expert panel of
not more than 13 members who are
drawn from the fields of bioethics,
science, medicine, technology,
engineering, law, philosophy, theology,
or other areas of the humanities or
social sciences. The Commission
advises the President on bioethical
issues arising from advances in
biomedicine and related areas of science
and technology. The Commission seeks
to identify and promote policies and
practices that ensure scientific research,
health care delivery, and technological
innovation are conducted in a socially
and ethically responsible manner.
The main agenda items for the
Commission’s twenty-third meeting are
to continue discussing the role of
deliberation and deliberative methods to
engage the public in bioethics, and how
to integrate pubic dialogue into the
bioethics conversation; bioethics
education as a forum for fostering
deliberative skills, and preparing
students to participate in public
dialogue in bioethics; goals and
methods of bioethics education; and
integrating bioethics education across a
range of professional disciplines and
educational levels. The draft meeting
agenda and other information about the
Commission, including information
about access to the webcast, will be
available at www.bioethics.gov.
The Commission welcomes input
from anyone wishing to provide public
comment on any issue before it.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
18:05 Oct 22, 2015
Jkt 238001
Respectful consideration of opposing
views and active participation by
citizens in public exchange of ideas
enhances overall public understanding
of the issues at hand and conclusions
reached by the Commission. The
Commission is particularly interested in
receiving comments and questions
during the meeting that are responsive
to specific sessions. Written comments
will be accepted at the registration desk
and comment forms will be provided to
members of the public in order to write
down questions and comments for the
Commission as they arise. To
accommodate as many individuals as
possible, the time for each question or
comment may be limited. If the number
of individuals wishing to pose a
question or make a comment is greater
than can reasonably be accommodated
during the scheduled meeting, the
Commission may make a random
selection.
Written comments will also be
accepted in advance of the meeting and
are especially welcome. Please address
written comments by email to info@
bioethics.gov, or by mail to the
following address: Public Commentary,
Presidential Commission for the Study
of Bioethical Issues, 1425 New York
Avenue NW., Suite C–100, Washington,
DC 20005. Comments will be publicly
available, including any personally
identifiable or confidential business
information that they contain. Trade
secrets should not be submitted.
Anyone planning to attend the
meeting who needs special assistance,
such as sign language interpretation or
other reasonable accommodations,
should notify Esther Yoo by telephone
at (202) 233–3960, or email at
Esther.Yoo@bioethics.gov in advance of
the meeting. The Commission will make
every effort to accommodate persons
who need special assistance.
Dated: October 9, 2015.
Lisa M. Lee,
Executive Director, Presidential Commission
for the Study of Bioethical Issues.
[FR Doc. 2015–26905 Filed 10–22–15; 8:45 am]
BILLING CODE 4154–06–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Advisory Committee on
Blood and Tissue Safety and
Availability
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services is hereby giving notice that the
Advisory Committee on Blood and
Tissue Safety and Availability
(ACBTSA) will hold a meeting. The
meeting will be open to the public.
DATES: The meeting will take place
Monday, November 9, 2015, from 8:00
a.m.–4:30 p.m. and Tuesday, November
10, 2015, from 8:00 a.m.–4:00 p.m.
ADDRESSES: Veterans’ Health
Administration National Conference
Center, 2011 Crystal Drive, 1st floor
Conference Center, Crystal City, VA
22202.
FOR FURTHER INFORMATION CONTACT: Mr.
James Berger, Designated Federal Officer
for the ACBTSA, Senior Advisor for
Blood and Tissue Policy, Office of the
Assistant Secretary for Health,
Department of Health and Human
Services, 1101 Wootton Parkway, Suite
250, Rockville, MD 20852. Phone: (240)
453–8803; Fax (240) 453–8456; Email
ACBTSA@hhs.gov.
SUPPLEMENTARY INFORMATION: The
ACBTSA provides advice to the
Secretary through the Assistant
Secretary for Health. The Committee
advises on a range of policy issues to
include: (1) Identification of public
health issues through surveillance of
blood and tissue safety issues with
national biovigilance data tools; (2)
identification of public health issues
that affect availability of blood, blood
products, and tissues; (3) broad public
health, ethical and legal issues related to
the safety of blood, blood products, and
tissues; (4) the impact of various
economic factors (e.g., product cost and
supply) on safety and availability of
blood, blood products, and tissues; (5)
risk communications related to blood
transfusion and tissue transplantation;
and (6) identification of infectious
disease transmission issues for blood,
organs, blood stem cells and tissues.
The Committee has met regularly since
its establishment in 1997.
In December 2013, the Committee
made recommendations regarding the
blood system. At that time, the
Committee expressed concern about the
ongoing reductions in blood use, the
number of large scale consolidations
occurring, the cost recovery issues for
blood centers, and the potential effects
on safety and innovation due to
instability. Past recommendations made
by the ACBTSA may be viewed at
www.hhs.gov/bloodsafety.
This meeting will provide a focused
examination of the mechanisms to fund
recently approved blood safety
innovations, such as pathogen
SUMMARY:
E:\FR\FM\23OCN1.SGM
23OCN1
Federal Register / Vol. 80, No. 205 / Friday, October 23, 2015 / Notices
reduction, bacterial testing, and
infectious disease testing. It is
anticipated that the implementation of
these blood safety innovations will
come with significant costs to blood
collection centers, and it remains
unclear how or if the blood industry can
afford such implementation. Speakers
will include a broad range of
stakeholders including blood banks,
physicians, blood purchasers, and
organizations that reimburse for blood
and blood products.
The public will have an opportunity
to present their views to the Committee
during a public comment session
scheduled for November 10, 2015.
Comments will be limited to five
minutes per speaker and must be
pertinent to the discussion. Preregistration is required for participation
in the public comment session. Any
member of the public who would like to
participate in this session is required to
contact the Designated Federal Officer at
his/her earliest convenience to register
for time (limited to 5 minutes);
registration must be completed prior to
close of business on November 2, 2015.
If it is not possible to provide 30 copies
of the material to be distributed at the
meeting, then individuals are requested
to provide a minimum of one (1) copy
of the document(s) to be distributed
prior to the close of business on
November 2, 2015. It is also requested
that any member of the public who
wishes to provide comments to the
Committee utilizing electronic data
projection submit the necessary material
to the Designated Federal Officer prior
to the close of business on November 2,
2015.
Dated: October 16, 2015.
James J. Berger,
Senior Advisor for Blood and Tissue Safety
Policy.
[FR Doc. 2015–26904 Filed 10–22–15; 8:45 am]
BILLING CODE 4150–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK4VPTVN1PROD with NOTICES
National Eye Institute; Notice of Closed
Meeting.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
VerDate Sep<11>2014
18:05 Oct 22, 2015
Jkt 238001
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel NEI Clinical and
Epidemiological Applications: Uveitis,
Cornea and Refractive Error.
Date: November 10, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Bethesda, 7301
Waverly Street, Bethesda, MD 20814.
Contact Person: JEANETTE M HOSSEINI,
Ph.D. Scientific Review Officer, 5635 Fishers
Lane, Suite 1300, Bethesda, MD 20892, 301–
451–2020, jeanetteh@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: October 19, 2015.
Natasha Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–26926 Filed 10–22–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Addictions, Depression, Bipolar
Disorder, Schizophrenia.
Date: November 10, 2015.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Samuel C. Edwards, Ph.D.,
IRG CHIEF, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
64425
Drive, Room 5210, MSC 7846, Bethesda, MD
20892, (301) 435–1246,
edwardss@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Psycho/Neuropathology, Lifespan
Development, and STEM Education.
Date: November 16–17, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Long Beach and Executive
Center, 701 West Ocean Boulevard, Long
Beach, CA 90831.
Contact Person: John H Newman, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3222,
MSC 7808, Bethesda, MD 20892, (301) 435–
0628, newmanjh@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Basic Research on HIV Persistence.
Date: November 18, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Fairmont Washington, DC, 2401
M Street NW., Washington, DC 20037.
Contact Person: Kenneth A. Roebuck,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5106,
MSC 7852, Bethesda, MD 20892, (301) 435–
1166, roebuckk@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Cell and Molecular Biology.
Date: November 18–19, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance Arlington Capital View,
2800 South Potomac Ave, Arlington, VA.
Contact Person: Maria DeBernardi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6158,
MSC 7892, Bethesda, MD 20892, 301–435–
1355, debernardima@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Dermatology, Rheumatology and
Inflammation.
Date: November 18, 2015.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Yanming Bi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4214,
MSC 7814, Bethesda, MD 20892, 301–451–
0996, ybi@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Learning, Memory, Language,
Communication and Related Neurosciences.
Date: November 18, 2015.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\23OCN1.SGM
23OCN1
]]>Agencies
[Federal Register Volume 80, Number 205 (Friday, October 23, 2015)]
[Notices]
[Pages 64424-64425]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-26904]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Advisory Committee on Blood and Tissue Safety and
Availability
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S.
Department of Health and Human Services is hereby giving notice that
the Advisory Committee on Blood and Tissue Safety and Availability
(ACBTSA) will hold a meeting. The meeting will be open to the public.
DATES: The meeting will take place Monday, November 9, 2015, from 8:00
a.m.-4:30 p.m. and Tuesday, November 10, 2015, from 8:00 a.m.-4:00 p.m.
ADDRESSES: Veterans' Health Administration National Conference Center,
2011 Crystal Drive, 1st floor Conference Center, Crystal City, VA
22202.
FOR FURTHER INFORMATION CONTACT: Mr. James Berger, Designated Federal
Officer for the ACBTSA, Senior Advisor for Blood and Tissue Policy,
Office of the Assistant Secretary for Health, Department of Health and
Human Services, 1101 Wootton Parkway, Suite 250, Rockville, MD 20852.
Phone: (240) 453-8803; Fax (240) 453-8456; Email ACBTSA@hhs.gov.
SUPPLEMENTARY INFORMATION: The ACBTSA provides advice to the Secretary
through the Assistant Secretary for Health. The Committee advises on a
range of policy issues to include: (1) Identification of public health
issues through surveillance of blood and tissue safety issues with
national biovigilance data tools; (2) identification of public health
issues that affect availability of blood, blood products, and tissues;
(3) broad public health, ethical and legal issues related to the safety
of blood, blood products, and tissues; (4) the impact of various
economic factors (e.g., product cost and supply) on safety and
availability of blood, blood products, and tissues; (5) risk
communications related to blood transfusion and tissue transplantation;
and (6) identification of infectious disease transmission issues for
blood, organs, blood stem cells and tissues. The Committee has met
regularly since its establishment in 1997.
In December 2013, the Committee made recommendations regarding the
blood system. At that time, the Committee expressed concern about the
ongoing reductions in blood use, the number of large scale
consolidations occurring, the cost recovery issues for blood centers,
and the potential effects on safety and innovation due to instability.
Past recommendations made by the ACBTSA may be viewed at www.hhs.gov/bloodsafety.
This meeting will provide a focused examination of the mechanisms
to fund recently approved blood safety innovations, such as pathogen
[[Page 64425]]
reduction, bacterial testing, and infectious disease testing. It is
anticipated that the implementation of these blood safety innovations
will come with significant costs to blood collection centers, and it
remains unclear how or if the blood industry can afford such
implementation. Speakers will include a broad range of stakeholders
including blood banks, physicians, blood purchasers, and organizations
that reimburse for blood and blood products.
The public will have an opportunity to present their views to the
Committee during a public comment session scheduled for November 10,
2015. Comments will be limited to five minutes per speaker and must be
pertinent to the discussion. Pre-registration is required for
participation in the public comment session. Any member of the public
who would like to participate in this session is required to contact
the Designated Federal Officer at his/her earliest convenience to
register for time (limited to 5 minutes); registration must be
completed prior to close of business on November 2, 2015. If it is not
possible to provide 30 copies of the material to be distributed at the
meeting, then individuals are requested to provide a minimum of one (1)
copy of the document(s) to be distributed prior to the close of
business on November 2, 2015. It is also requested that any member of
the public who wishes to provide comments to the Committee utilizing
electronic data projection submit the necessary material to the
Designated Federal Officer prior to the close of business on November
2, 2015.
Dated: October 16, 2015.
James J. Berger,
Senior Advisor for Blood and Tissue Safety Policy.
[FR Doc. 2015-26904 Filed 10-22-15; 8:45 am]
BILLING CODE 4150-41-P
